Biofrontera Inc. (BFRI)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$0.8909−12.23%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $13.2M
- Forward P/E
- 2.1
- 52-week range
- $0.555 – $1.66
- 52-week change
- −2.40%
- EPS (trailing)
- −$0.43
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $41.7M (+11.75%)
- Net income
- −$10.5M
- Operating margin
- −27.2%
- Diluted EPS
- −$1.04
- Free cash flow
- −$13.4M
From the company’s annual report on SEC EDGAR.
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Headquarters: Woburn, United States · 84 employees · biofrontera-us.com